Evogene to Present at the H.C. Wainwright 24th Annual Global Investment Conference



Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the “Company“, “Evogene“), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene’s President and CEO, will attend virtually and present at the H.C. Wainwright 24th Annual Global Investment Hybrid Conference, 2022, taking place from September 12-14, 2022, in New York and also in a virtual format.

Mr. Haviv’s presentation will focus on Evogene’s disruptive technologies, its AI engines for biologic product discovery and development, and the ecosystem of product-focused subsidiaries and partnerships it has built around its technologies. The presentation will be available from the H.C. Wainwright conference website from 7am ET on Monday, September 12, 2022.

Mr. Haviv will also be available for 1-1 meetings with current and prospective investors via video conference on Tuesday, September 13, 2022. Interested investors are welcome to contact Evogene’s Investor Relations team whose contact details are below, or for H.C. Wainwright clients, schedule meetings directly via the conference’s online meeting platform.